No Data
No Data
Coherus to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined With Toripalimab in HNSCC and Gastric Cancer
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab